Met-Enkephalin (Menk)

Overview:

Met-Enkephalin, also known as Opioid Growth Factor (OGF), is an endogenous pentapeptide with potent immunomodulatory, anti-cancer, and pain-relieving properties. It binds to opioid receptors and the Opioid Growth Factor Receptor (OGFr), where it plays a role in regulating cell proliferation, modulating immune responses, and offering analgesia. Its therapeutic potential spans oncology, inflammation, autoimmunity, and neurodegeneration.

Brief History:

Discovered in the 1970s as part of research into endogenous opioid peptides, Met-Enkephalin was initially explored for its pain-relieving effects. Later, scientists identified its unique role in cell cycle regulation and immune function via interaction with OGFr. This led to clinical interest in MENK as a biologic regulator in cancer therapy and immune-based disorders. It has been investigated in China and Europe for its use in treating hepatocellular carcinoma, pancreatic cancer, and multiple sclerosis.

Therapeutic Uses:

1. Cancer Immunotherapy Support:
   • Purpose: Inhibits tumor cell proliferation through OGFr signaling.
   • Benefits: May reduce tumor growth and support anti-cancer therapies.
   • Dosage Example: 10 mg subcutaneously 3x weekly in oncology research protocols.
2. Autoimmune Disorders:
   • Purpose: Modulates immune cell activity and inflammation.
   • Benefits: Can help regulate immune responses in conditions like MS or Crohn’s disease.
   • Dosage Example: 5–10 mg subcutaneously 2–3 times weekly.
3. Neurological Protection and Repair:
   • Purpose: Supports neuron regeneration and reduces neuroinflammation.
   • Benefits: May aid in recovery from neurodegenerative conditions and stroke.
   • Dosage Example: 5 mg SC 3x weekly, under physician supervision.
4. Chronic Pain and Inflammatory Conditions:
   • Purpose: Provides opioid-like pain relief without addiction risk.
   • Benefits: Reduces chronic pain, inflammation, and improves quality of life.
   • Dosage Example: 5–10 mg SC up to 3x weekly as needed.
5. Immune System Modulation and Longevity Research:
   • Purpose: Regulates immune surveillance and cellular growth cycles.
   • Benefits: Supports healthy immune aging and immune rebalancing.
   • Dosage Example: 10 mg SC weekly or biweekly for longevity applications.

Dosage and Administration:

• Reconstitution:
  • Reconstitute 10 mg with 1 mL bacteriostatic water for a 10 mg/mL concentration.
• Typical Dose Range:
  • 5 mg to 10 mg per dose, 1–3 times per week depending on clinical goals.

Method of Administration:

• Subcutaneous (Sub-Q) Injection: Primary method due to bioavailability and ease of use.

Duration of Use:

• Short-Term Cycles (Pain or Inflammation): 2–6 weeks.
• Extended Protocols (Cancer, Neuroprotection): 2–6 months or longer depending on response.

Phases of Treatment:

1. Initial Phase:
   • Begin with 5 mg SC 2x/week to monitor response and tolerance.
2. Maintenance Phase:
   • 5–10 mg SC 2–3x/week depending on symptom stability.
3. Longevity Phase:
   • Long-term cycling (e.g., 10 mg weekly) for immune and regenerative support.

General Considerations:

• Monitoring: Immune markers, inflammation labs, pain scores, and tumor markers if used in oncology.
• Side Effects: Typically well-tolerated. Rarely mild injection site irritation or fatigue.
• Contraindications: None widely reported, though caution in active immunosuppressed states is advised.

Conclusion:

Met-Enkephalin is a unique therapeutic peptide that bridges analgesic, immunoregulatory, and regenerative medicine. Its versatility makes it an intriguing candidate in integrative oncology, autoimmune care, and neurotherapeutics. With appropriate dosing and monitoring, MENK offers strong potential for improving immune resilience and recovery.

Category: Immunomodulatory / Neuroactive Peptide